Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $53.5300 (-0.11%) ($53.5300 - $53.5300) on Fri. Jan. 8, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.2% (three month average) | RSI | 58 | Latest Price | $53.5300(-0.11%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 0.6% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Rotation from value to growth for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(66%) ARKG(62%) ARKK(58%) IBB(58%) IWO(58%) | Factors Impacting TGTX price | TGTX will decline at least -3.1% in a week (0% probabilities). VIXM(-41%) VXX(-36%) UUP(-19%) UNG(-3%) TLT(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.1% (StdDev 6.2%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $52.23(2.49%) | 10 Day Moving Average | $52.27(2.41%) | 20 Day Moving Average | $51.32(4.31%) | To recent high | -2.2% | To recent low | 112.3% | Market Cap | $6.78b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |